RANCHO CUCAMONGA, CA / ACCESS Newswire / April 6, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") announced today that Bill Peters, CFO, Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, and Dan Dischner, SVP of Corp. Communication, will be presenting at the 25th Annual Needham Healthcare Conference on Tuesday, April 14, 2026, at 11:45 am ET. For access to the webcast, visit Amphastar Pharmaceuticals' website at http://ir.amphastar.com.

SG Americas Securities LLC purchased a new stake in Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 93,515 shares of the company's stock, valued at approximately $2,504,000. SG Americas Securities LLC owned about 0.20%

Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH - Get Free Report)'s share price crossed below its two hundred day moving average during trading on Tuesday. The stock has a two hundred day moving average of $25.36 and traded as low as $19.27. Amphastar Pharmaceuticals shares last traded at $19.59, with a volume of 534,127 shares. Analysts Set

Amphastar Pharmaceuticals, Inc. (AMPH) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Amphastar Pharmaceuticals (AMPH) is rated a Buy, with ~81% upside to a $33 fair value, despite margin pressures for 2026. AMPH faces declining sales in legacy products but expects mid- to high-single-digit revenue growth in 2026, led by Baqsimi and new launches. I estimate operating margin to dip to 22% in 2026 due to increased expenses, recovering to 26% by 2030 as higher-margin pipeline products ramp up.

Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH - Get Free Report) shares reached a new 52-week low during mid-day trading on Friday. The stock traded as low as $19.54 and last traded at $20.44, with a volume of 726331 shares. The stock had previously closed at $19.96. Analysts Set New Price Targets AMPH has been the topic

Amphastar Pharmaceuticals remains a 'Hold' as growth and margin headwinds persist amid its transition from generics to a proprietary pipeline. AMPH's legacy generics are declining, branded products face growth deceleration, and margins are pressured by product mix and rising R&D/SG&A costs. FY26 revenue guidance was cut to mid- to high-single-digit growth; AMP-007's contribution is uncertain, and preclinical pipeline catalysts are years away.

Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH - Get Free Report) gapped down prior to trading on Friday after Wells Fargo and Company lowered their price target on the stock from $34.00 to $30.00. The stock had previously closed at $26.49, but opened at $22.44. Wells Fargo and Company currently has an overweight rating on the

Although the revenue and EPS for Amphastar (AMPH) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Amphastar Pharmaceuticals, Inc. (AMPH) Q4 2025 Earnings Call Transcript